Adverum Biotechnologies Announces Presentation of Preclinical Long-Term Safety Data of ADVM-022 at 2019 Angiogenesis, Exudation, and Degeneration Conference
February 11, 2019 08:30 ET
|
Adverum Biotechnologies, Inc.
Data demonstrates long-term expression of ADVM-022, an intravitreally delivered gene therapy currently in phase 1 for wet AMD, does not affect retinal morphology in non-human primates Initial...
Adverum Biotechnologies Provides 2019 Outlook
January 06, 2019 20:00 ET
|
Adverum Biotechnologies, Inc.
MENLO PARK, Calif., Jan. 06, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare...
Adverum to Present at the 37th Annual J.P. Morgan Healthcare Conference
December 20, 2018 08:30 ET
|
Adverum Biotechnologies, Inc.
MENLO PARK, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare...
Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources
December 03, 2018 16:10 ET
|
Adverum Biotechnologies, Inc.
MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare...
Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy
December 03, 2018 08:30 ET
|
Adverum Biotechnologies, Inc.
MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare...
Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration
November 19, 2018 08:30 ET
|
Adverum Biotechnologies, Inc.
ADVM-022 is the first intravitreally delivered gene therapy utilizing directed evolution AAV.7m8 vector for wet AMDOPTIC trial to evaluate single administration of ADVM-022 for wet AMDInterim trial...
Adverum to Present at 30th Annual Piper Jaffray Healthcare Conference
November 13, 2018 16:30 ET
|
Adverum Biotechnologies, Inc.
MENLO PARK, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare...
Adverum Biotechnologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 08, 2018 16:10 ET
|
Adverum Biotechnologies, Inc.
MENLO PARK, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare...
Adverum Biotechnologies Provides Program Updates
November 01, 2018 16:15 ET
|
Adverum Biotechnologies, Inc.
Preliminary data from the ADVANCE Phase 1/2 Study in A1AT deficiency showed ADVM-043 in doses of up to 1.5 x 1013 vg/kg were safely administered and well tolerated; Protein expression did not meet a...
Adverum Biotechnologies Announces Appointment of Leone Patterson as CEO and Member of the Board of Directors
October 17, 2018 16:10 ET
|
Adverum Biotechnologies, Inc.
MENLO PARK, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular...